Cryoablation Focus Sanarus specializes in minimally invasive cryoablation for breast tumors with FDA clearance for fibroadenomas and active clinical study for early-stage cancer, presenting a clear value proposition for breast centers seeking non-surgical treatment options.

Market Expansion The Visica 2 Treatment System is already deployed at participating U.S. breast centers, indicating opportunities to partner with additional centers, expand adoption, and participate in concurrent clinical studies such as FROST.

Regulatory & Trials Engage in opportunities around ongoing and upcoming trials (like FROST) to gain access to early adopter sites, collect real-world data, and strengthen case studies for payer and physician education.

Strategic Partnerships Board-level and executive changes in the past years suggest a capacity for strategic partnerships and potential co-development or joint commercialization ventures to accelerate market penetration.

Financial & Scale Small company revenue in the low millions with a lean workforce implies high impact from scalable sales channels, distributor partnerships, and targeted medical device procurement programs at larger hospital systems.